CL2017000560A1 - Fórmula que incluye glicopirrolato, método y sistema - Google Patents
Fórmula que incluye glicopirrolato, método y sistemaInfo
- Publication number
- CL2017000560A1 CL2017000560A1 CL2017000560A CL2017000560A CL2017000560A1 CL 2017000560 A1 CL2017000560 A1 CL 2017000560A1 CL 2017000560 A CL2017000560 A CL 2017000560A CL 2017000560 A CL2017000560 A CL 2017000560A CL 2017000560 A1 CL2017000560 A1 CL 2017000560A1
- Authority
- CL
- Chile
- Prior art keywords
- glycopyrrolate
- magnesium stearate
- formula
- crushed
- jet mill
- Prior art date
Links
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 title abstract 4
- 229940015042 glycopyrrolate Drugs 0.000 title abstract 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 6
- 235000019359 magnesium stearate Nutrition 0.000 abstract 3
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Amplifiers (AREA)
- Saccharide Compounds (AREA)
Abstract
<p>Se divulga un método para la elaboración de una composición farmacéutica para administración pulmonar que comprende co-triturar en molino de chorro glicopirrolato y estearato de magnesio, caracterizado porque el glicopirrolato y el estearato de magnesio co-triturados en molino de chorro son luego sometidos a una etapa de acondicionamiento la cual incluye la exposición del glicopirrolato y el estearato de magnesio co-triturados en molino de chorro a humedad.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14184164 | 2014-09-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000560A1 true CL2017000560A1 (es) | 2018-03-16 |
Family
ID=51542160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000560A CL2017000560A1 (es) | 2014-09-09 | 2017-03-08 | Fórmula que incluye glicopirrolato, método y sistema |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US10532041B2 (es) |
| EP (2) | EP3191081B1 (es) |
| JP (1) | JP6502501B2 (es) |
| KR (1) | KR101927960B1 (es) |
| CN (1) | CN106604720B (es) |
| AP (1) | AP2017009777A0 (es) |
| AR (1) | AR101793A1 (es) |
| AU (1) | AU2015314272B2 (es) |
| BR (1) | BR112017003888B1 (es) |
| CA (1) | CA2960694C (es) |
| CL (1) | CL2017000560A1 (es) |
| CO (1) | CO2017003056A2 (es) |
| CY (1) | CY1124569T1 (es) |
| DK (1) | DK3191081T3 (es) |
| DO (1) | DOP2017000065A (es) |
| EA (1) | EA037332B1 (es) |
| EC (1) | ECSP17021465A (es) |
| ES (1) | ES2793905T3 (es) |
| HR (1) | HRP20201005T1 (es) |
| HU (1) | HUE049339T2 (es) |
| IL (1) | IL250427A0 (es) |
| LT (1) | LT3191081T (es) |
| MA (2) | MA40617B1 (es) |
| MX (1) | MX373939B (es) |
| MY (1) | MY181647A (es) |
| NZ (1) | NZ728435A (es) |
| PH (1) | PH12017500303B1 (es) |
| PL (1) | PL3191081T3 (es) |
| PT (1) | PT3191081T (es) |
| RS (1) | RS60299B1 (es) |
| SG (1) | SG11201700536XA (es) |
| SI (1) | SI3191081T1 (es) |
| SM (1) | SMT202000280T1 (es) |
| SV (1) | SV2017005403A (es) |
| TN (1) | TN2017000077A1 (es) |
| TW (1) | TWI602566B (es) |
| UA (1) | UA115958C2 (es) |
| WO (1) | WO2016038116A1 (es) |
| ZA (1) | ZA201700658B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3009923T3 (en) * | 2017-03-15 | 2025-03-31 | Vectura Ltd | Method and formulation |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN116194087B (zh) * | 2020-01-15 | 2025-07-11 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| CN116115590B (zh) * | 2023-01-17 | 2025-12-05 | 上海方予健康医药科技有限公司 | 一种用于制备吸入粉雾剂的方法 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| SE9302777D0 (sv) | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| GB9808470D0 (en) | 1998-04-22 | 1998-06-17 | Smithkline Beecham Plc | Novel process and apparatus |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB9826286D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| AU2001249479A1 (en) | 2000-04-11 | 2001-10-23 | Dura Pharmaceuticals, Inc. | Physically stabilized dry powder formulations |
| DE60130657T2 (de) | 2000-07-20 | 2008-07-03 | Campina Nederland Holding B.V. | Methode zur herstellung eines kristallinen tablettierungshilfstoffes, der so erhaltene hilfsstoff und seine verwendung |
| NZ526059A (en) | 2000-11-30 | 2005-05-27 | Vectura Ltd | Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition |
| GB0030074D0 (en) | 2000-12-08 | 2001-01-24 | Univ London Pharmacy | Particulate inhalation carrier |
| US7309707B2 (en) | 2002-03-20 | 2007-12-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament |
| DE10212264A1 (de) | 2002-03-20 | 2003-10-02 | Boehringer Ingelheim Pharma | Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels |
| ITMI20022674A1 (it) | 2002-12-18 | 2004-06-19 | Chiesi Farma Spa | Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione. |
| US20040121003A1 (en) | 2002-12-19 | 2004-06-24 | Acusphere, Inc. | Methods for making pharmaceutical formulations comprising deagglomerated microparticles |
| US7188993B1 (en) * | 2003-01-27 | 2007-03-13 | Harold W Howe | Apparatus and method for resonant-vibratory mixing |
| GB0321607D0 (en) | 2003-09-15 | 2003-10-15 | Vectura Ltd | Manufacture of pharmaceutical compositions |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| JO3102B1 (ar) | 2004-03-17 | 2017-09-20 | Chiesi Framaceutici S P A | صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة |
| GB0409703D0 (en) * | 2004-04-30 | 2004-06-02 | Vectura Ltd | Pharmaceutical compositions |
| GB0410398D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0410399D0 (en) | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| GB0425758D0 (en) | 2004-11-23 | 2004-12-22 | Vectura Ltd | Preparation of pharmaceutical compositions |
| US20060292077A1 (en) | 2005-03-18 | 2006-12-28 | Zhao Jonathon Z | Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| US8074906B2 (en) | 2005-07-07 | 2011-12-13 | Nanotherapeutics, Inc. | Process for milling and preparing powders and compositions produced thereby |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0525254D0 (en) | 2005-12-12 | 2006-01-18 | Jagotec Ag | Powder compositions for inhalation |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| JP5283835B2 (ja) * | 2006-07-06 | 2013-09-04 | 東京エレクトロン株式会社 | マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP1944018A1 (en) | 2007-01-10 | 2008-07-16 | CHIESI FARMACEUTICI S.p.A. | Micronised particles of low-dosage strength active agents for powder formulations for inhalation |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| US20110105449A1 (en) | 2007-11-07 | 2011-05-05 | Astrazeneca R&D | Dry powder formulations comprising ascorbic acid derivates |
| RU2482838C2 (ru) | 2007-12-13 | 2013-05-27 | Новартис Аг | Органические соединения |
| BRPI0820745A2 (pt) | 2007-12-13 | 2015-06-16 | Novartis Ag | Compostos orgânicos |
| US8235314B2 (en) | 2009-02-12 | 2012-08-07 | Linde Aktiengesellschaft | Nonequilibrium humidity control for jet milling |
| ES2617680T3 (es) | 2009-04-09 | 2017-06-19 | Novartis Ag | Proceso para la preparación de sales de pirrolidinio |
| UA110773C2 (uk) | 2009-04-24 | 2016-02-25 | Айсьютіка Пті Лтд | Спосіб одержання порошків, що містять нано- і мікрочастинки |
| MX336414B (es) * | 2010-04-01 | 2016-01-19 | Chiesi Farma Spa | Proceso de preparacion de particulas portadoras para polvos secos para inhalacion. |
| AU2011244384B2 (en) | 2010-04-21 | 2016-06-23 | Chiesi Farmaceutici S.P.A. | "Process for providing particles with reduced electrostatic charges" |
| EP2954888A1 (en) | 2010-08-31 | 2015-12-16 | GlaxoSmithKline Intellectual Property Development Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| KR20140012989A (ko) | 2011-02-17 | 2014-02-04 | 시플라 리미티드 | 글리코피롤레이트 및 베타2-효능제의 조합 |
| JO3510B1 (ar) * | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| AU2011368334A1 (en) | 2011-05-17 | 2013-11-21 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of two or more active agents |
| GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
| US20150202297A1 (en) | 2012-07-05 | 2015-07-23 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| US20150202148A1 (en) | 2012-07-05 | 2015-07-23 | Arven llac Sanayi Ve Ticaret Anonim Sirketi | Dry powder inhalers comprising a carrier other than lactose |
| DE102012211907A1 (de) * | 2012-07-09 | 2014-01-09 | Robert Bosch Gmbh | Drehschlagschrauber mit einem Schlagwerk |
| GB201305825D0 (en) | 2013-03-28 | 2013-05-15 | Vectura Ltd | New use |
| EP2999460A1 (en) | 2013-05-22 | 2016-03-30 | Pearl Therapeutics, Inc. | Compositions, methods&systems for respiratory delivery of three or more active agents |
| US20160317391A1 (en) | 2013-12-17 | 2016-11-03 | Merck Sharp & Dohme Corp. | Media milling process for the manufacture of active pharmaceutical ingredients in propellants |
-
2015
- 2015-09-09 PT PT157625955T patent/PT3191081T/pt unknown
- 2015-09-09 EP EP15762595.5A patent/EP3191081B1/en active Active
- 2015-09-09 NZ NZ728435A patent/NZ728435A/en unknown
- 2015-09-09 BR BR112017003888-9A patent/BR112017003888B1/pt active IP Right Grant
- 2015-09-09 LT LTEP15762595.5T patent/LT3191081T/lt unknown
- 2015-09-09 TN TN2017000077A patent/TN2017000077A1/en unknown
- 2015-09-09 HU HUE15762595A patent/HUE049339T2/hu unknown
- 2015-09-09 KR KR1020177009495A patent/KR101927960B1/ko active Active
- 2015-09-09 RS RS20200579A patent/RS60299B1/sr unknown
- 2015-09-09 JP JP2017532216A patent/JP6502501B2/ja active Active
- 2015-09-09 HR HRP20201005TT patent/HRP20201005T1/hr unknown
- 2015-09-09 PL PL15762595T patent/PL3191081T3/pl unknown
- 2015-09-09 AU AU2015314272A patent/AU2015314272B2/en active Active
- 2015-09-09 AR ARP150102874A patent/AR101793A1/es not_active Application Discontinuation
- 2015-09-09 CA CA2960694A patent/CA2960694C/en active Active
- 2015-09-09 EA EA201790544A patent/EA037332B1/ru unknown
- 2015-09-09 TW TW104129823A patent/TWI602566B/zh active
- 2015-09-09 ES ES15762595T patent/ES2793905T3/es active Active
- 2015-09-09 MA MA40617A patent/MA40617B1/fr unknown
- 2015-09-09 US US15/509,769 patent/US10532041B2/en active Active
- 2015-09-09 SI SI201531220T patent/SI3191081T1/sl unknown
- 2015-09-09 EP EP20165232.8A patent/EP3689332B1/en active Active
- 2015-09-09 MY MYPI2017700336A patent/MY181647A/en unknown
- 2015-09-09 SG SG11201700536XA patent/SG11201700536XA/en unknown
- 2015-09-09 AP AP2017009777A patent/AP2017009777A0/en unknown
- 2015-09-09 UA UAA201703025A patent/UA115958C2/uk unknown
- 2015-09-09 WO PCT/EP2015/070660 patent/WO2016038116A1/en not_active Ceased
- 2015-09-09 MA MA050680A patent/MA50680A/fr unknown
- 2015-09-09 SM SM20200280T patent/SMT202000280T1/it unknown
- 2015-09-09 CN CN201580048064.1A patent/CN106604720B/zh active Active
- 2015-09-09 DK DK15762595.5T patent/DK3191081T3/da active
- 2015-09-09 MX MX2017003080A patent/MX373939B/es active IP Right Grant
-
2017
- 2017-01-26 ZA ZA2017/00658A patent/ZA201700658B/en unknown
- 2017-02-02 IL IL250427A patent/IL250427A0/en active IP Right Grant
- 2017-02-17 PH PH12017500303A patent/PH12017500303B1/en unknown
- 2017-03-07 SV SV2017005403A patent/SV2017005403A/es unknown
- 2017-03-08 DO DO2017000065A patent/DOP2017000065A/es unknown
- 2017-03-08 CL CL2017000560A patent/CL2017000560A1/es unknown
- 2017-03-29 CO CONC2017/0003056A patent/CO2017003056A2/es unknown
- 2017-04-06 EC ECIEPI201721465A patent/ECSP17021465A/es unknown
-
2019
- 2019-12-03 US US16/701,616 patent/US20200155506A1/en not_active Abandoned
-
2020
- 2020-06-17 CY CY20201100560T patent/CY1124569T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000632A1 (es) | Composición y método para el tratamiento del autismo. | |
| MX2017001971A (es) | Composiciones antimetanogenicas y sus usos. | |
| MX380762B (es) | Composiciones farmacéuticas que comprenden meloxicam. | |
| MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
| TW201613901A (en) | New compounds | |
| MX2016011810A (es) | Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso. | |
| IN2013MU03583A (es) | ||
| MX387235B (es) | Derivados de pirazolopiridina y su uso en terapia | |
| MD20170048A2 (ro) | Formulare pe bază de acetat de abirateronă şi procedee de utilizare a acesteia | |
| MX370628B (es) | Composiciones y metodos para tratar las espinillas. | |
| MX2016013236A (es) | Formulacion inmunosupresora. | |
| MX2021000773A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| HK1243636A1 (zh) | 用於治疗代谢疾病和癌症的新的线粒体解偶联剂 | |
| ZA201701000B (en) | Attenuated bovine coronavirus and related vaccines | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| DOP2017000058A (es) | Derivados de tetrahidroquinolina como inhibidores del bromodominio | |
| IN2013MU03373A (es) | ||
| CL2017000560A1 (es) | Fórmula que incluye glicopirrolato, método y sistema | |
| AU2015267160A8 (en) | Methods and compositions for preventing ischemia reperfusion injury in organs | |
| MX384259B (es) | Composiciones y metodos para tratamiento de crecimiento celular anormal. | |
| IN2014CH00840A (es) | ||
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| RU2014154366A (ru) | Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний | |
| IN2014CH00035A (es) |